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Spectrophotometric Method for the Assay of Human Blood
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Chromogenic substrate
Abstract. A spectrophotometric method for the assay of human blood coagulation factor
vIII in plasma is presented. The chromogenic assay for factor VIII:C in plasma is performed
in 3 steps: (l) activation of factor VIII by thrombin; (2) activation of factor X in a mixture of
factor X, factor IXa, phospholipids/Ca2t and plasma containing activated factor VIII, and(3) determination of the rate of factor Xa formation with the chromogenic substrate 52337.
Within-assay variation was between 5 and 6.90/o for factor vIII:C activities between 20 and
1500/0. Clotting and chromogenic factor vIII:C actiyities were compared in plasma of 50
normal healthy donors (coefficient of correlation r: 0.g3).
Introduction
Factor VIII or anrihemophilia globulin A
is a plasma protein that is essential for nor-
mal hemostasis (see [l] for review). Its con-
genital absence is by far the most common
cause of congenital bleeding tendency. The
procoagulant protein (factor VIII:C) occurs
in plasma tightly bound to the von Wille-
brand factor (factor VIII:vWF). Factor
VIII:C and vWF together form the factor
VIII complex. Factor VIII:C appears respon-
sible for normal thrombin formation,
whereas factor VIII:vWF is required for
platelet-vessel wall interaction. (For reviews
on factor VIII complex and vWF see [2, 3].)
If factor VIII:C is congenitally deficient, fac-
tor VIII:vWF is normal. If factor VIII:vWF
is deficient, factor VIII:C is to a varying
degree also.
A widely used method to determine fac-
tor VIII in plasma is the l-stage clotting
assay introduced in 1962 by Hardisty et al.
[a]. This assay is based on the property of
factor VIII to correct the prolonged clotting
time of hemophiliac plasma to a degree de-
termined by the amount of factor VIII
present.
A new assay method for the determina-
tion of factor VIII using a chromogenic sub-
strate for factor Xa appeared feasible after
kinetic studies on the role of factor VIII in
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the intrinsic factor-X-activating complex [ 5]'
In this paper, we describe a spectrophoto-
metric assay for factor VIII in human plasma
and compare the properties and precision of
the assay with the l-stage clotting assay.
Materials and Methods
S2 33 7, Bz-Ile-Glu(Piperidyl)-Gly-Arg-p-nitroani-
lide and S2238, H-D-Phe-Pip-Arg-p-nitroanilide were
obtained from Kabi AB, Sweden. Egg-phosphatidyl-
choline (egg-PC) was from Koch-Light, UK, and
brain-phospharidylserine (brain-PS) was from Sigma,
St. Louis, Mo., USA. Hirudin was from Pentapharm'
Basel, Switzerland. Fatty acid free human albumin
and soybean trypsin inhibitor were obtained from
Sigma. Factor-deficient plasmas were purchased from
George King Biomedical, Overland Park, Kans',
USA. The batch numbers used were factor VIII, GK
837-314; high molecular weight kininogen, GK 1603-
D30; factor XII, GK 1202-921; factor XI, GK I I l0-
Nl9; prekallikrein, GK 1704-124; passavoy GK
1501-625: factor V. GK 503-223, and von Wille-
brand, GK 1403-93. The factor-deficient plasmas
from General Diagnostics were of the following lot
numbers: factor VIII, 4G926', factor X, 4H699; factor
VII, 4J759. Factor-Vlll-defrcient plasma (WH) and
factor-IX-deficient plasma were obtained from local
patients. Kaolin (light) was ftom Koch-Light. Inosi-
thin was from Associated Concentrates, New York,
USA.
Proleins
Bovine factor X (factor X2 was used in this work),
factor IXa and thrombin were purihed and activated
as published before [5]. Phospholipid vesicles consist-
ing of 400/o brain-PS and 600/o egg-PC were made by
sonication at 0'C in a buffer of 50mM tris-HCl,
l75mM NaCl, pH 7.9, as described before [6].
Human Donor Plasmas
Blood was obtained from healthy volunteers after
informed consent by venipuncture using a 1.2 X
40 mm needle, discarding the first 2 ml. Blood (9 ml)
was mixed with I ml of O.l M trisodium citrate in a
plastic tube and centrifuged for 30 min at 2,000 81.
The plasma was aspirated and made platelet-free by a
centrifugation at 4"C for 15 min at 14,000g in the
Beckmann J-21 rotor. The plasma samples were fro-
zen and stored at - 70 'C in small portions. Reference
pool plasma was made by mixing I ml of each of the
donor plasmas (n : 50). It is assumed that factor
VIII:C activity in the reference plasma is I U/ml. Dif-
ferent dilutions of the reference pool were used to
obtain standard c-q reference curves.
Spectrophotometric Assay for Faclor VIII
(Standard Factor VIII AssaY)
Forty microliters of human plasma (or a sample in
which factor VIII must be determined) is added to a
prewarmed mixture of 910 pl buffer containing
175 mM NaCl, 50 mM tr is-HCl, pH 7.9, 0.5 mg/ml
human albumin and 50 pl of 60 nM (6 NIH U/ml) of
thrombin. After incubation for I min at 37 " C, 500 ptl
of the plasma, containing activated factor VIII, is
added to a second tube containing 450 pl of a pre-
warmed (37 'C) mixture of phospholipids, CaCl2 and
factor IXa. Factor X activation is started by addition
to the reaction mixture of 50 pl of l0 pM factor X, at
the same time as the activated plasma. Tbe final com-
position of the reaction mixture (1 ml) is: 20 pl of
plasma, added as 500 pl thrombin-activated plasma;
0.5 1tM factor X, 50 nM factor IXa, 20 pM phospho-
l ipid vesicles (40molo/o PS/60 mol0/o PC); l .5nM
thrombin, 0.5 mg/ml human albumin in a buffer con-
taining 175 m-44 NaCl, 5O mM tris-HCl (pH 7.9) and
6mM CaClz.
After I and 2 min, samples from the reaction mix-
ture (usually 0.1 ml) were added to a cuvette (37 "C)
with 0.8 ml buffer of 175 m-l.1NaCl, 50 m,l'1tris-Hcl'
pH 7.9, 2OnM EDTA, 0.5 antithrombin units of
hirudin and 0.5 mglml human albumin. After addr-
t ion  o f  0 .1  ml  52337 (2 .35mM;25 A316 un i ts /ml ) ,
the absorbance increase at 405 nm was recorded for
2-3 min using a Beckman Model 25 spectrophotome-
ter. From the absorbance change, the amount of fac-
tor Xa present was calculated using a calibration
curve made with a factor Xa preparation of known
concentration. The rate of factor Xa formation was
calculated from the amount offactor Xa present after
I and 2 min and was corrected for the rate found in'a
blank experiment run without plasma.
Factor VIII Clotting AssaY
A l-stage clotting assay for factor VIII [4] was car-
ried out by preincubating for 6 min at 37 "C 50 pl
factor-Vlll-deficient plasma, 50 pl kaolin-inosithin in
Michaelis buffer, and 50 pl of the factor VIII sample.
r-
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After 6 min, 50 pl l/30 M CaClt was added to start
clot formation. The clotting time was determined by
tilting the tubes. The amount of factor VIII present
was determined from a reference curve. This curve is
a double logarithmic plot of the clotting times (deter-
mined in duplicate) of 10 different dilutions of refer-
ence plasma. The composition of Michaelis buffer
was 0.0285 M Na acetate, 0,0285 M Na barbiturate,
0. I  l6 M NaCl (pH 7.a). The kaol in-inosithin suspen-
sion contained 5 mg/ml kaolin and I mg/ml inosi-
thin
Statistical Analysis of Data
The significance of differences between 2 values
was tested by a paired Student t tesr. CV is the coet
ficient of variation, the standard deviation is ex-
pressed as a percentage ofthe mean.
Results
Determination of Optimal Assay
Conditions
In intrinsic factor X activation, factor X
is cleaved to factor Xa by the enzyme factor
IXa, and the rate of this reaction is strongly
enhanced in the presence of the nonenzy-
matic accessory components, i.e. activated
factor VIII and phospholipids. Factor VIIIa
works by at least 2 different mechanisms: it
increases the affinity of factor IXa for bind-
ing to phospholipids [7] by a factor ofabout
100 and it also increases the V-u* turnover
number of factor Xa formation by factor IXa
about 1,000-fold [5]. The experimental con-
ditions for the factor VIII assay in plasma as
described in 'Materials and Methods' were
based on the observations done in purified
systems [5, 7]. The factor X concentration in
the assay (0.5 ttM) was chosen well above the
K. for factor X (0.06 tt@. A phospholipid
vesicle concentration of 20 pM was selected
in the assay because the rate of factor Xa
formation strongly increases between 0 and
5 pM, reaches a plateau between l0 and
50 1tM, and decreases at higher phospholipid
concentration. The factor IXa concentration
used in the assay is 50 n41 and is based on
the experiment shown in figure l. The rate of
factor Xa formation increases with the factor
IXa concentration and levels off at higher
factor IXa concentrations. In the absence of
plasma factor VIII, a low rate of factor Xa
formation proportional with factor IXa is
found. When this rate is subtracted from the
rate measured in the presence of plasma, a
plateau level is obtained, indicating appar-
ent saturation of the factor-X-activating sys-
tem with factor IXa. A factor IXa concentra-
tion in the assay of 5OnM approaches satu-
ration. When 20 pl plasma is present in the
assay, the background rate without plasma is
about 100/o of the rate measured in the pres-
ence of plasma.
Factor VIII must be activated before i1
can participate in factor X activation, and
thrombin is a well-known activator of factor
VIII. Activated factor VIII is not stabile and
rapidly inactivates [2, 6]. Therefore, the acti-
vation of factor VIII in plasma by thrombin
was carried out in a 1-min period just before
the start ofeach factor X activation reaction.
Optimal conditions for activation were es-
tablished by the experiments shown in frg-
ure 2. Plasma was incubated at varying
thrombin concentrations and after I min,
the activated plasma sample was transferred
to a mixture of phospholipid, Ca2* and fac-
tor IXa. Simultaneous with the activated
plasma, factor X was added and the time
course of factor Xa formation was deter-
mined during 3 min. As shown in figure 2,
no factor X activation is found within 3 min
when thrombin is omitted from the plasma
activation mixture. The rate of factor Xa for-
mation increases when increased amounts of
thrombin a1e used (0-1.8 nI4)to activate the
Fig. l. Deter:
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Fig. l. Determination of the optimal factor IXa
concentration. Forty microliter of reference pool
plasma was added to 960 pl of a prewarmed (37'C)
solut ion of 3.0nM thrombin in a buffer containing
5OmM tr is-HCl, l ' /5mM NaCl, pH 7.9. and
0.5 mg/ml of human albumin After exactly I min at
37 "C, 500 pl of the plasma thrombin mixture was
transferred to a second prewarmed tube containing
450 pl of a mixture of phospholipids, CaCl2 and vary-
ing amounts of factor IXa. Together with the acti-
vated plasma, 50 pl of factor X ( l0 p,tf) was added to
start factor Xa formation. After I and 2 min, samples
of 100 pl were added to prewarmed (37'C) cuvettes
containing 0.8 ml of a buffer containing 50 mM tr is-
HCl, 175mM NaCl, 20mM EDTA, pH 79, and,
0.5 mg/rnl human albumin. To the cuvette was added
0. I ml chromogenic substrate 52337 (2.35 m,rl4). The
absorbance change at 405 nm was measured and used
to calculate the amount of factor Xa present as de-
scribed in 'Materials and Methods'. The composition
of the factor-X-activating mixture of I ml was: 20 pl
human plasma, 1.5 n,]ly'thrombin, 20 pMphospholipid
vesicles consisting of40 0/o phosphatidylserine and 60 0/o
phosphatidylcholine, factor IXa as indicated in the fig-
ure,0.5 pMfactor X, 50 mMtris-Hcl, 175 m,4,1NaCl,
6 mM CaCl1 pH 7 .9, and 0.5 mg/ml human albumin
r : Without plasma; r : with reference pool plasma;
o: difference curve obtained by substraction.
factor VIII present. No further increase (or
decrease) in the time course of factor Xa for-
mation was observed at thrombin concentra-
tions between 1.8 and 6 n 11. This result sug-
gests that optimal activation of factor VIII in
plasma is obtained under these conditions.
The amounts of thrombin did not influence
the factor Xa generation by a factor-Vlll-
independent mechanism, as no aclivity was
observed when factor VIII was absent (frg. 1)
(see also below). Hence, in the standard as-
say procedure, plasma is activated for I min
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at a thrombin concentration of 3 nM. The
time course of factor Xa formation was li-
near for at least 2 min, and the rate of factor
Xa formation was calculated from the
amount of factor Xa present after I and
2 min.
Hirudin is present in the cuvettes to in-
hibit the activity of thrombin on the chro-
mogenic substrate 52337. Thrombin is
formed from prothrombin present in the
plasma sample during the factor X activa-
tion reaction. In the standard factor VIII
assay containing 20 pl plasma, 27 nM
thrombin is formed after 2 min. The throm-
bin concentration was determined using
52238 as the chromogenic substrate for
thrombin in a cuvette that contained soy-
bean trypsin inhibitor to inactivate factor
Xa. Addition of hirudin (0.5 antithrombin
units per cuvette) inhibited the thrombin
activity on 52238 for 97.80/0. A much larger
Fig.2. Determination of the optimal thrombin
concentration for the activation of factor VIII in
human plasma Pool plasma (40 pl) was added to
960 pl of a buffer (37 "C) containing 50 m,t l tr is-HCl,
175mM NaCl, pH 7.9, 0.5 mg,/ml human albumin
and varying amounts of thrombin (0-6 nM\ as indi-
cated. After I min, 500 pl of the thrombin-aclivated
plasma was transferred to a reaction mixture for fac-
tor X activation, as described in the legend of fig-
ure l. The rate of factor Xa formation was as deter-
mined as in figure I from the amounts of factor Xa
present after I and 2 min. The final composition of
the reaction mixture ( I ml) was: 20 pl human plasma,
20 pM phospholipid, 50 nM facror IXa, 0.5 pM fac-
tor X, 50 mM tris-HCl, 175 mM NaCl, 6 mM CaCl2,
pH 7.9, and 0.5 mg/ml human albumin.
excess of hirudin (5-50 antithrombin units
per cuvette) could not be used, since the
hirudin preparation partially inhibited the
activity of factor Xa on 52337. When in the
standard factor VIII assay hirudin was omit-
ted from the cuvettes, 3.2 + 2.4o/o (mean +
SD; n: I I l), higher rates of factor X activa-
tion were found, indicating that the contri-
bution of thrombin to the total hydrolysis of
52337 is relatively small.
Properties of the Spectrophotometric
Assay
Linearity of the Assay. Varying amounts
of reference pool plasma were added to our
standard test system. As shown in hgure 3, a
linear dependence between the rate offactor
Xa formation and the plasma concentration
is found between 5 and 30 pl of plasma per
milliliter reaction mixture. High amounts of
plasma in the assay give rise to clot forma-
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Fig.3.  L inear i ty  of  the assay.  V2rying
amounts of reference pool plasma were in-
cubaled wi th 1.0 nM of  thrombin in I  ml .
Af ter  I  min at  37'C.  500 ul  of  the mixture
was t ransfcrrcd to 500 ul  ofa reacl ion mix-
ture for factor X activation. The amounl of
factor Xa formed was determined after I
and 2 min,  as descr ibed in the legcnd of
figure I The reaction mixture with the
amounls of  act ivated plasma as indicated
contained I 5 nM thrombin and further
components for faclor X activation as de-
scr ibed in the lcgend of f igure 2.  An amount
of20 pl  ofreference pool  p lasma in the fac-
tor X activalion mixture was chosen as the
condition for the standard factor VIII as-
say, the rate of factor Xa formation found
was desisnated as the I U/ml value.
tion in the factor X activation mixture,
which prevents accurate sampling. In the low
range, a slight deviation from linearity is
found. The same line is seen when the
plasma samples are diluted in factor-Vlll-
deficient plasma. In the standard factor VIII
assay, an amount of 20 pl plasma per millili-
ter reaction mixture is present. If values of
below 200/o of normal are to be expected in
the abnormal sample, the sample volume is
increased so as to ensure the equivalent
amount of at least 2 pl of normal plasma fac-
tor VIII in the test.
To demonstrate that the spectrophoto-
metric assay depends on factor VIII and not
on other clotting factors, we determined the
factor VIII activity with the 2 assays in var-
ious factor-deficient plasmas. The results
shown in table I indicate that background
activity is measured in 3 different factor-
Vlll-deficient plasmas and in plasma. of a
patient with severe von Willebrand's dis-
ease. All other plasmas show factor VIII ac-
tivities in the 2 assays comparable to the
activities of normal individuals (frg. 4). This
Table L Factor VIII content of various factor-defi-
cient plasmas determined with the chromogenic assay
and a clotting assay
Deficient plasma Factor VIII ,  U/ml
spectrophoto- clotting
metnc assay assay
Factor XII
Factor XI
High molecular
weight kininogen
Prekallikrein
Passovoy
Factor V
Factor IX
Factor VII
Factor X
von Willebrand
Factor VIII (WH)
Factor VIII
(George King)
Factor VIII
(Gen. Diagnostics)
0.70
0 .82
0.46
1 . 0 5
0.42
1 . 3 1
0 .33
0  6 r
0.'79
0.05
0.05
0.05
0.05
0 .7  6
0.'76
0.60
0 .7  6
0.68
1 4 0
0 4 0
0.84
0.80
0.04
0.01
0.01
0.02
Factor VIII was assayed as described in 'Materials
and Methods'. Values in italics were obtained usine
undiluted plasma.
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result and the observation that the plasma
dilution curves made in buffer (frg. 3) and in
factor-VllI-deficient plasma are overlapping
indicate that the assay is not affected by
other plasma components.
Within-Assay Precision and Between-
Assay Precision. Precision of the 2 assays is
shown in table II. Within-assay precision
was estimated by testing several dilutions of
the reference pool plasma l0 times each.
Variation was expressed as percentage of the
mean activity in plasma.
Between-assay precision of the chromo-
genic assay was determined by use of the ref-
erence pool plasma, stored in small portions
aI -70 "C. On l0 consecutive days, I portion
was assayed, from which the between-assay
Fig.4. Comparison of factor VIII
activity determined by chromogenic
and by clotting assay in 50 normal indi-
viduals. Blood was collected from
healthy volunteers. Plasma preparation
and the assays for factor VIII were car-
ned out as described in 'Materials and
Methods'.  For 50 normal samoles: v:
0 .0883 +  0 .949x ' ,  r :0 .82 .
variation was calculated. Considerably
smaller assay variations are observed from
the chromogenic factor VIII assay than for
the factor VIII clotting assay.
Comparison of the Chromogenic Method
with the Clotting Assay - Variation in Factor
VIII Activity in Normal Individuals. We de-
termined factor VIII activity with the chro-
mogenic method and the clotting assay in
plasma of 50 healthy volunteers (30 men and
20 women). The results are shown in fig-
ure 4. The coefficient of correlation between
the 2 assay methods is 0.82. The mean, the
range and the interindividual variation for
the 2 assays are presented in table III. No
significant differences in factor VIII activity
were observed between males and females.
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Table Ir. within- and between-assay precision of the chromogenic and clotting assay
Assay Within-assav variation. o/o
0.  l0  0.20 0.50
U/ml U/ml U/ml
l  .0  1.5 2.0
U/ml Uiml U/ml
Between-
assay
variation, o/o
Factor VIII chromogenic assay
Factor VIII clotting assay
t t .1  6.5
18.6 2r .0
5.0 6.9
t 7 . 5
5.3
17.9
9 . 5
28.4
The I U/ml value of factor VIII in the chromogenic assay represents 20 pt of human reference pool plasma
in the final reaction mixture of I ml. The 1000/o value in the clotting assay is defined as the clotting trme
obtained when 0.1 ml ofa l:20 dilution ofthe reference pool plasma is clotted in a l-stage clotting assay for
factor VIII with a final reaction volume of 0.4 ml. Reference pool plasma was obtained from 50 subjectively
healthy donors (30 men, 20 women). Within-assay variation: coeffrcient of variation for measurements on the
same day. Between-assay variation: coefficient of variation for measurements on different days.
Table III. Variation in normal values
Mean Inter-
factor VIII individual
activity, U/ml variation, o/o
Coefficient
of variation
assay, %
Range
U/ml
Mean Rale of Xa
AA 405/min formarion,
nM/min
Factor VIII
chromogenic assay
3 0 M
2 0 F
50
l . l  3
1 .23
l - l  I
32.9
24.8
29.7
2 .85
3 .  l 0
0.53-2.29 0.0203
0.73-r.97 0.0221
6.9 0.53-2.29 0.0210 2.95
Factor VIII
clotting assay
3 0 M
2 0 F
50
1 .07
t .23
l . l 4
26.2
24.8
26.3 r7 .5
0.68-  1.87
0.78-1.86
0.68-  r .87
n: Number ofdonors; AA: absorbance change. The interindividual variation equals variation in normal
values (see table II).
Discussion
In this paper, a spectrophotometric
method for the determination of factor VIII
in human plasma is presented. The method
is based on the role of factor VIII as a non-
enzymatic cofactor in intrinsic factor X acti-
vation. The assay consists of 3 steps: (1) in-
cubation for I min of plasma (or a sample
containing factor VIII) with thrombin to
conyert factor VIII to factor VIIIa; (2) incu-
bation for 2 min of factor VIIIa with factor
IXa, factor X and phospholipid./Ca2* to al-
low factor Xa formation, and (3) determina-
tion of the amount of factor Xa in samples
taken after I and 2 min. Factor Xa is mea-
sured with the chromogenic substrate 52337
in the presence of EDTA to stop further fac-
22 van Dieijen/van Dieijen-Visser/Franssen/Hemker Spectrophotor
tor X activation. The rate of factor Xa for-
mation is calculated and compared to the
rate found with reference plasma. Factor
VIII activity is expressed in units per millili-
ter, assuming that the factor VIII activity in
reference pool plasma is I U/ml.
The components used in the chromogenic
assay are bovine clotting factors IXa, X and
thrombin that were prepared by standard
procedures and commercial available phos_
pholipids. Saturating (excess) concentrations
of factors IXa, X and phospholipids were
chosen to minimize variations due to a slight
activity change that might occur in these
preparations.
Factor VIII was activated in a separate
step at an optimal concentration of throm_
bin. When thrombin was omitted, no mea_
surable amount of factor Xa is formed
within the assay period of 2 min. Factor Xa
formation starts after 5-6 min, presumably
as a result offactor VIII activation by traces
of factor Xa and./or thrombin formed during
the lag period. The frnding that optimal fac_
tor VIII activation by thrombin could be
obtained suggests that all factor VIII is con-
verted to factor VIIIa. Consequently, the as_
say responds to the total concentration of
factor VIII, irrespective of the activity state
of factor VIII. By performing the factor VIII
assay without thrombin, it might be possible
to detect circulating factor VIIIa. The few
plasma samples we have tested so far with-
out thrornbin showed no evidence for a pres_
ence of factor VIIIa.
The rate of factor Xa formation we find
in plasma (3 nM Xalmin) is proportional to
the plasma factor VIII concentration and
can be used to calculate the plasma factor
VIII concentration. The thrombin activation
experiments and the factor IXa saturation
curve indicate that all plasma factors VIII
participate in factor X activation. When it is
assumed that factor VIII functions in a one-
to-one stoichiometrical complex with factor
IXa in the enzymatic unit, then the rate of
factor Xa formation is proportional to the
concentration of the limiting component in
the complex, which is here the factor VIIIa
concentration.
The maximal rate of factor Xa formation
is 925 mol Xalmin/mol enzyme. This indi-
cates that 3.0/925 nM factor VIII is present
in the reaction mixture. In the assay, plasma
is diluted l:50, and hence, the plasma VIII
concentration in plasma is 150/925
0.16 nM + 320/0. This value is in agreement
with estimates by immunological methods
I2l.
The sensitivity of the chromogenic assay
extends to plasma factor VIII levels of about
0.05 U/ml, but at factor VIII concentrations
of 0.10U/ml and lower, the coefficient of
variation increases. Low levels of factor VIII
can be detected by including larger sample
volumes in the reaction mixture. When fac-
tor VIII is determined in plasma, not more
than 40 pl plasma can be used if fibrin for-
mation in the factor X activation mixture
may preyent accurate sampling to the cu_
vette. Defibrination by Arvin is useful in
that case. The absorbance change found after
2 min of factor Xa formation under standard
conditions (20 pl plasma per milliliter reac_
tion mixture and 100 pl sample per cuvette)
is 0.0210 AA405/min. Up to lO-fold higher
absorbance changes when a larger fraction of
the reaction mixture is transferred to the
cuYette.
The coefficient of variation of the chro_
mogenic assay varies between 5-7o/o. where_
as the precision of the clotting assay
varies between 17 and 2lo/o. The same large
assay variations of the clotting method have
been obsen
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:
been observed in previous studies [4, 8, 9].
The diversity in reagents, methods and
equipment hat is used in clotting assays may
account for the large inter_laboratory varia-
tion observed in factor VIII determinations
[0]. Introduction of the chromogenic assay
with its superior reproducibility may allow
standardization.
A spectrophotometric assay for factor
VIII has been presented by Ros6n et al. [1 l,
l2l working at KabiVitrum Diagnostica. De-
tails of their assay have not been disclosed,
but as the assay presented here, their method
is based on the factor X activation reaction.
The precision and sensitivity of the Kabi
assay is similar to ours.
Several groups have used immunora-
diometric assays to quantify factor-Vlll-
coagulant antigen in plasma [3-17]. Hu-
man allogeneic antibodies are used in these
assays obtained from hemophilia A patients
with circulating anti-VIII:C antibodies that
developed after infusions of factor VIII
preparations or from individuals that devel-
oped these antibodies spontaneously. The
radioimmune assays are very sensitive and
have been used to detect factor VIII levels of
0.01-0.03 U/ml. The method depends on
the availability of the antibodies which may
prevent large-scale application; moreover,
immunological methods are complicated by
the fact that immunologically recognized
factor VIII:C may not be functionally active
in clotting reactions [13].
Factor VIII in normal individuals varied
between 0.53 and 2.27 Ulml, what results in
a variation in normals of 29.7 o/o. Previously,
we found a variation for factors VII, IX, X
and prothrombin of 21.4, 11.0, 15.0, and
12.0o/o, respectively I I 8], suggesting that the
factors VII and VIII present in plasma in the
lowest concentration and the shortest half-
life tend to have the largest biological varia-
tron.
Factor VIII assays are carried out to de-
tect hemophilia, to identify carriers of hemo-
philia, to check the potency of factor VIII
preparations used to treat hemophilia and to
control treatment.
For prenatal diagnosis of hemophilia
[4], the assay can easily be scaled down
such that the test can be carried out with
small plasma volumes obtained by fetoscopy
l t 7 ,  l 8 l .
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